AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
Anti-Cspg4 Fusions with Type I Interferon for the Treatment of Malignancy
Technology Benefits
The fused anti-CSPG4/interferon has shown high efficacy in inhibiting the growth of melanoma cell lines in cell culture and in immunodeficient mice.
Technology Application
This technology can be used for treatment of a range of human cancers, including:MelanomaMultiple myelomaGliomaTriple-negative breast cancerChronic lymphocytic leukemia
Detailed Technology Description
UCLA researchers have developed antibody-IFN fusion proteins to selectively localize IFN at tumor sites. The fusion proteins were shown to inhibit the growth of melanoma cell lines in vitro and in vivo.
Others
State Of Development
Significant pre-clinical data has been obtained.
Background
Interferons (IFNs) are proteins made by the host cell in response to pathogens that are potent regulators of cell growth. In addition, IFNs possess inhibitory effects against many human cancers. However, since less than 0.01% of injected IFNα reaches the desired target tumor sites, the therapeutic cannot achieve effective concentrations at the tumor sites without also introducing significant systemic toxicity. Therefore, there exists an unmet need to develop antibodies to carry IFNs directly to cancer sites.
